Evidence map›Paper›PMID 42634707›Full record

ArticleEJHaem2026

Complement-Dominant Relapse of Mixed Autoimmune Hemolytic Anemia After Rituximab Response.

Naru Tomigaki, Seiji Kakiuchi, Akimasa Sakamoto, Shutaro Fujioka, Isamu Harima, Hiroaki Akiyama, Ryotaro Niwa, Ikumi Takagi, Yoko Kozuki, Yoshiharu Miyata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Naru Tomigaki *Department of Hematology Yodogawa Christian Hospital Osaka Japan.
Seiji Kakiuchi *Department of Hematology Yodogawa Christian Hospital Osaka Japan.
Akimasa SakamotoDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Shutaro FujiokaDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Isamu HarimaDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Hiroaki AkiyamaDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Ryotaro NiwaDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Ikumi TakagiDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Yoko KozukiDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.
Yoshiharu MiyataDepartment of Artificial Intelligence and Digital Health Science Kobe University Graduate School of Medicine Kobe Japan.
Sou TanakaDepartment of Clinical Laboratory Yodogawa Christian Hospital Osaka Japan.
Hiroyuki TsujiDepartment of Clinical Laboratory Yodogawa Christian Hospital Osaka Japan.
Nobuko IwataDepartment of Hematology Yodogawa Christian Hospital Osaka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mixed autoimmune hemolytic anemia (AIHA) may show temporal shifts in its predominant effector mechanism. Methods: We serially assessed clinical course, direct antiglobulin test (DAT) specificity, cold agglutinin activity, complement markers, marrow findings, and immunofixation after rituximab response. Results: During winter relapse, the previously identified Conclusions: Serial reassessment may identify complement-mediated relapse in mixed AIHA. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

clonal B‐cell populationcold agglutinincomplementmixed autoimmune hemolytic anemiarituximabsutimlimab

Identifiers

PMID42634707
PMCPMC13500038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.